Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy.

@article{Isojrvi1993PolycysticOA,
  title={Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy.},
  author={Jouko Isoj{\"a}rvi and Timo J. Laatikainen and Arto J. Pakarinen and Kaisa Juntunen and Vilho V. Myllyl{\"a}},
  journal={The New England journal of medicine},
  year={1993},
  volume={329 19},
  pages={
          1383-8
        }
}
BACKGROUND Reproductive endocrine disorders are more common among women with epilepsy than among normal women. These disorders have been attributed to epilepsy itself, but could be related to antiepileptic-drug therapy. METHODS We studied 238 women with epilepsy who were seen regularly at the Outpatient Department of the University Hospital, Oulu, Finland. Their mean age was 33 years (range, 18 to 45), and the mean duration of therapy was 9 years (range, 0 to 31). Twenty-nine (12 percent… 
Polycystic ovaries, obesity and insulin resistance in women with epilepsy
TLDR
The frequency of PCOs in 27 % of epileptic women seems to be similar to that in the general population with a frequency of 20–30 %, which indicates that VPA increases glucose stimulated pancreatic insulin secretion, which might be followed by an increase in body weight.
Valproate, hyperandrogenism, and polycystic ovaries: a report of 3 cases.
TLDR
The 3 cases presented here illustrate the development of reproductive endocrine disorders after the initiation of valproate therapy in women with epilepsy, characterized by hyperandrogenism and polycystic ovaries in all cases, and were associated with weight gain and menstrual disorders in 2 of the 3 women.
Obesity, polycystic ovarian syndrome and thyroid dysfunction in women with epilepsy
TLDR
WWE on VAL and CBZ had significant weight gain compared to DPH users and there was no difference in the incidence of PCOS between the users of VAL, CBZ and DPH.
Ovarian structural disturbances in epilectic patients treated with Sodium Valproate
TLDR
This study supports the association of polycystic ovaries and high BMI with VPA treatment and the frequency of menstrual disturbances did not differ significantly between the two groups.
A Putative Relationship between Valproic Acid and Polycystic Ovarian Syndrome: Implications for Treatment of Women with Seizure and Bipolar Disorders
TLDR
Evidence bearing on a putative relationship between VPA and bipolar disorder in women with epilepsy and polycystic ovarian syndrome is reviewed.
Polycystic Ovary Syndrome and Epilepsy
TLDR
On the whole these studies suggest that women with epilepsy are at risk for developing reproductive endocrine disorders, even if there is not yet definite evidence that PCOS may be over-represented in these patients nor that VPA may be the cause of endocrine problems.
On the Association Between Valproate and Polycystic Ovary Syndrome
TLDR
There are no reliable data on the actual prevalence of polycystic ovary syndrome in normal women and in women with epilepsy, and there is no reason to contraindicate the use of VPA in womenWith epilepsy, but patients should be informed about the risk of weight gain and its consequences.
Polycystic ovary syndrome in patients on antiepileptic drugs
TLDR
The study observed significantly higher occurrence of PCO in patients on VPA compared to other AEDs and the normal population, and VPA group (Epilepsy + BPAD) had a significantlyHigher occurrence of obesity than other treatment groups.
Endocrine and metabolic changes in women with polycystic ovaries and polycystic ovary syndrome
TLDR
The prevalence of the isolated ultrasonographic finding of polycystic ovaries (PCO) in the Finnish population and among women with a history of gestational diabetes (GDM) and changes in the present carbohydrate metabolism were investigated and the nature of the ovarian streoidogenic response of women with PCOS to exogenously administered human chorionic gonadotrophin, human menotrophins and follicle stimulating hormone was evaluated.
...
...